New combo therapy shows promise for rare blood cancer
NCT ID NCT07233720
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This study looks at how well a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo and be followed to see if their tumors shrink or disappear. The goal is to control the disease, not cure it, and researchers will also track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.